Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DRAXIS Specialty Pharmaceuticals, a subsidiary of Jubilant Pharmova, is a Canadian-based pharmaceutical company specializing in radiopharmaceuticals and contract manufacturing services. The company operates through two primary business units: Jubilant DraxImage, which focuses on diagnostic and therapeutic radiopharmaceuticals for nuclear medicine, and Jubilant HollisterStier, which provides contract manufacturing for sterile and non-sterile products. Their product portfolio includes imaging agents for various medical conditions, including lung, liver, and kidney disorders, as well as thyroid cancer treatments. With a significant manufacturing facility in Kirkland, Quebec, DRAXIS serves a global market, providing critical medical isotopes and specialized drug delivery formats like lyophilized vials. The company is recognized for its expertise in technetium-99m generators and specialized imaging agents used in oncology, cardiology, and neurology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DRAXIS Specialty Pharmaceuticals.